Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Schistosoma mansoni | hypothetical protein | 0.0123 | 0.3042 | 0.3627 |
Trypanosoma brucei | C-8 sterol isomerase, putative | 0.0362 | 1 | 0.5 |
Loa Loa (eye worm) | fli-1 protein | 0.0215 | 0.572 | 0.5126 |
Schistosoma mansoni | thyroid hormone receptor | 0.0133 | 0.333 | 0.4312 |
Trypanosoma cruzi | C-8 sterol isomerase, putative | 0.0362 | 1 | 0.5 |
Brugia malayi | Fli-1 protein | 0.0215 | 0.572 | 0.4954 |
Mycobacterium ulcerans | glutamine-binding lipoprotein GlnH | 0.0019 | 0 | 0.5 |
Mycobacterium tuberculosis | Probable glutamine-binding lipoprotein GlnH (GLNBP) | 0.0019 | 0 | 0.5 |
Echinococcus multilocularis | Mitotic checkpoint protein PRCC, C terminal | 0.0123 | 0.3042 | 0.9076 |
Treponema pallidum | amino acid ABC transporter, periplasmic binding protein (hisJ) | 0.0019 | 0 | 0.5 |
Schistosoma mansoni | ets-related | 0.0215 | 0.572 | 1 |
Chlamydia trachomatis | glutamine binding protein | 0.0019 | 0 | 0.5 |
Echinococcus multilocularis | thyroid hormone receptor alpha | 0.0133 | 0.333 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0362 | 1 | 1 |
Echinococcus multilocularis | GA binding protein alpha chain | 0.0071 | 0.1519 | 0.4188 |
Chlamydia trachomatis | arginine ABC transporter substrate-binding protein ArtJ | 0.0019 | 0 | 0.5 |
Leishmania major | C-8 sterol isomerase-like protein | 0.0362 | 1 | 0.5 |
Schistosoma mansoni | thyroid hormone receptor | 0.0133 | 0.333 | 0.4312 |
Treponema pallidum | amino acid ABC transporter, periplasmic binding protein | 0.0019 | 0 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0185 | 0.4845 | 0.4129 |
Echinococcus granulosus | GA binding protein alpha chain | 0.0071 | 0.1519 | 0.4615 |
Echinococcus granulosus | Mitotic checkpoint protein PRCC C terminal | 0.0123 | 0.3042 | 1 |
Loa Loa (eye worm) | D-ets-4 DNA binding domain-containing protein | 0.0071 | 0.1519 | 0.0341 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.